NSCLC (Non-small Cell Lung Carcinoma)Phase 2NCT07551414

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

A Phase 2 study testing Zorifertinib Plus Intra-Ommaya CSF Chemotherapy in people with NSCLC (Non-small Cell Lung Carcinoma) and Leptomeningeal Metastasis, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences at 1 site in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts

Official record

Search all trials

Trial summary

A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy Read more about this study

Who is it for?: Ages 18 to 75 years
Conditions the study is for: NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation
What is being tested?: Zorifertinib Plus Intra-Ommaya CSF Chemotherapy
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 38 participants
Where: 1 siteChina
Study dates: 30 May 2026to 30 May 2028
Phase: Phase 2
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 75 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

1. Have fully understood the study and voluntarily signed the Informed Consent Form (ICF).
2. Subjects must be 18-75 years old before signing the Informed Consent Form (ICF).
3. During the screening phase, subjects must be diagnosed with non-small cell lung cancer (NSCLC) and test positive for EGFR-sensitive mutations (L858R and/or Exon 19Del).
4. Subjects who developed leptomeningeal progression after treatment with third-generation EGFR-TKIs and have no extracranial progression. The original third-generation EGFR-TKIs may be continued at the original dose or reduced dose.
5. Subjects diagnosed with leptomeningeal metastasis must have positive cerebrospinal fluid (CSF) cytology results. Subjects with negative CSF cytology but clinically diagnosed leptomeningeal metastasis based on symptoms, brain or spinal MRI imaging are also eligible for enrollment.
6. Subjects with both leptomeningeal progression and brain parenchymal progression are allowed to enroll.

Show all 17Show fewer

7. Have undergone Ommaya reservoir implantation, with confirmation of no surgery-related complications and normal function of the Ommaya reservoir.
8. If accompanied by neurological symptoms, the following conditions must be met: able to take oral medication and swallow drugs; no need to increase hormone dosage to control central nervous system symptoms for at least 1 week prior to study treatment (i.e., symptom stability).
9. All anti-tumor therapy-related toxicities must have recovered to ≤ Grade 1 per CTCAE 5.0 criteria prior to starting study treatment (neurotoxicity related to platinum-based therapy may recover to ≤ Grade 2 per CTCAE 5.0 criteria); alopecia of any grade is allowed for enrollment.
10. Screening period test results must meet the following criteria:
Neutrophil count ≥ 1.5 × 10⁹/L
Platelet count ≥ 100 × 10⁹/L
Hemoglobin ≥ 90 g/L
Serum creatinine ≤ 1.5 × ULN, or creatinine clearance (calculated via Cockcroft-Gault formula) ≥ 50 mL/min
Total serum bilirubin ≤ 1.5 × ULN (≤ 3 × ULN allowed for patients with Gilbert syndrome or liver metastasis)
Aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN allowed for patients with liver metastasis)
Alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN allowed for patients with liver metastasis) 11. Estimated survival duration ≥ 3 months. 12. Karnofsky Performance Status (KPS) score ≥ 60.

Who cannot join

1. Subjects with a history of cranial or spinal radiotherapy within 6 months prior to study drug administration are ineligible for enrollment. Radiotherapy for bone metastases within 3 months prior to study drug administration is also not permitted.
2. Subjects who have undergone major surgical procedures (e.g., intrathoracic, intra-abdominal, or pelvic surgery) within 4 weeks prior to the first dose of study treatment, or who have not yet recovered from side effects related to such surgeries, are ineligible for enrollment.
3. Subjects with any other currently active malignant tumor besides NSCLC are excluded.
4. Subjects with clinically significant, uncontrolled cardiac disease and/or cardiac events occurring within the past 6 months, such as:
Myocardial infarction within 6 months prior to screening;
Documented history of heart failure (NYHA Class III-IV);

Show all 21Show fewer

Uncontrolled hypertension: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, regardless of antihypertensive medication use (adjustment of antihypertensive drugs prior to screening is permitted);
Drug-refractory arrhythmias;
Screening QTcF >470 ms;
Left ventricular ejection fraction (LVEF) <50%. 5. Subjects with gastrointestinal diseases or severe impairment of gastrointestinal function that may significantly affect drug absorption (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
6. Subjects unable to discontinue the following medications within 1 week prior to study drug administration and during the study period:
Strong inducers or strong inhibitors of CYP3A4;
Drugs that may prolong the QT interval or induce torsades de pointes. 7. Subjects with prior or current HIV infection are excluded. HCV antibody-positive subjects may be enrolled if HCV RNA is undetectable (with the lower limit of detection defined per each center's standards) and there is no concurrent hepatitis B virus (HBV) infection. HBV-infected subjects may be enrolled if they meet the following conditions:
For active hepatitis B patients: at least 6 weeks of antiviral therapy prior to starting study treatment, with HBV DNA <100 IU/mL and ALT/AST levels <ULN;
For resolved or chronic hepatitis B patients: at least 2 weeks of prophylactic antiviral therapy prior to starting study treatment, with HBV DNA below 100 IU/mL (e.g., inactive carriers) and ALT/AST levels <ULN.
8. Pregnant or breastfeeding women; women of childbearing potential must agree to use highly effective contraception during the treatment period and for 3 months after the last dose; fertile men must also use highly effective contraception during the treatment period and for 6 months after the last dose.
9. Subjects with a prior history of interstitial lung disease, including clinically significant radiation pneumonitis (e.g., affecting daily life or requiring therapeutic intervention).
10. Subjects who have previously received zorifertinib or its active pharmaceutical ingredient.
11. Known hypersensitivity to zorifertinib's active ingredients, excipients, or drugs with similar chemical structures or classes.
12. Subjects with other comorbid diseases or factors that, in the investigator's judgment, would pose excessive risk to the subject upon participation in the clinical trial.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Wan Jinghai, Professor contact

8610-87788495

wanjinghai@sina.com

China1 site

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing
National Cancer Center/Cancer Hospital, 8610-87788495, cancergcp@163.com

Other trials in China

About this study

Official title: A Prospective Study of Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Therapy

A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy

Read the detailed description

This study is a prospective clinical trial evaluating the preliminary efficacy and safety of zorifertinib combined with intra-Ommaya reservoir cerebrospinal fluid (CSF) chemotherapy in patients with non-small cell lung cancer (NSCLC) who develop leptomeningeal progression after prior third-generation EGFR-TKI therapy.

The study will enroll patients with advanced NSCLC harboring EGFR-sensitive mutations (L858R and/or Exon 19Del) who experience leptomeningeal progression without concurrent extracranial disease progression following third-generation EGFR-TKI treatment. A total of 38 participants are planned for enrollment. Upon enrollment, participants will receive oral zorifertinib plus pemetrexed administered via the Ommaya reservoir for CSF chemotherapy, alongside standard clinical care. Treatment will continue until disease progression, occurrence of intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of informed consent, loss to follow-up, death, or any other circumstance deemed by the investigator as requiring treatment discontinuation-whichever occurs first.

Conditions: NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation, Zorifertinib
Being tested: Zorifertinib Plus Intra-Ommaya CSF Chemotherapy
Keywords: Leptomeningeal Metastasis, NSCLC, zorifertinib, EGFR-TKI Sensitizing Mutation
Medical subject headings: Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Zorifertinib Plus Intra-Ommaya CSF ChemotherapyDrug
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Therapy

Study groups in NCT07551414
Study group	Role	What they receive
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy	Experimental	Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Therapy Receives: Drug: Zorifertinib Plus Intra-Ommaya CSF Chemotherapy

What is being measured

The primary outcome is the main question the study is designed to answer.

Response Assessment in Neuro - Oncology Leptomeningeal Metastases (RANO - LM) criteria
RANO-LM uses a categorical classification (no single numeric score range) to define disease status:
Complete Response (CR): All LM-related lesions disappear, no increase in ventricular size.
Partial Response (PR): All measurable LM nodules shrink by ≥50% (sum of perpendicular diameters), no increase in ventricular size.
Stable Disease (SD): Neither PR nor Progressive Disease (PD) criteria are met.
Progressive Disease (PD): Any of the following:
1. New measurable LM nodule(s);
2. ≥50% increase in the product of perpendicular diameters of any measurable nodule (≥25% if the largest diameter is <10mm);
3. ≥25% increase in Evan's index (marker of hydrocephalus progression);
4. New linear meningeal enhancement (excluding post-lumbar puncture changes).
Measured: Until the end of the study (up to 3 years)

Secondary outcomes (1)

Overall Survival (OS)
Overall Survival (OS)
Measured: Until the end of the study (up to 3 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 May 202630 May 2028

First posted24 Apr 2026
Study start30 May 2026 (estimated)
Primary completion30 May 2027 (estimated)
Study completion30 May 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (8)Papers the sponsor has linked to this study.
Other trials for NSCLC (Non-small Cell Lung Carcinoma)Studies of the same condition, open and under way.
More trials run by Cancer Institute and Hospital, Chinese Academy of Medical SciencesThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Model description: This study is a single-center, single-arm, open-label, prospective clinical study.
Masking: None (open label)
Enrolment: 38 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07551414
Sponsor's protocol ID: NCC6051
Status last verified: Apr 2026
First submitted: 17 Apr 2026
Last updated: 24 Apr 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: all IPD collected throughout the trial

Publications

Fan C, Jiang Z, Teng C, Song X, Li L, Shen W, Jiang Q, Huang D, Lv Y, Du L, Wang G, Hu Y, Man S, Zhang Z, Gao N, Wang F, Shi T, Xin T. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial. ESMO Open. 2024 Apr;9(4):102384. doi: 10.1016/j.esmoop.2024.102384. Epub 2024 Feb 19.
PubMed 38377785
Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Gao F, Song X, Jiang Q, Huang D, Jin Y, Lv Y, Wei L, Shi T, Zhao X, Gao N, Jiang Z, Xin T. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615). J Thorac Oncol. 2021 Aug;16(8):1359-1368. doi: 10.1016/j.jtho.2021.04.018. Epub 2021 May 11.
PubMed 33989780
Montes de Oca Delgado M, Cacho Diaz B, Santos Zambrano J, Guerrero Juarez V, Lopez Martinez MS, Castro Martinez E, Avendano Mendez-Padilla J, Mejia Perez S, Reyes Moreno I, Gutierrez Aceves A, Gonzalez Aguilar A. The Comparative Treatment of Intraventricular Chemotherapy by Ommaya Reservoir vs. Lumbar Puncture in Patients With Leptomeningeal Carcinomatosis. Front Oncol. 2018 Nov 20;8:509. doi: 10.3389/fonc.2018.00509. eCollection 2018.
PubMed 30524956
Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006 Jan;7(1):41-53. doi: 10.1038/nrn1824.
PubMed 16371949
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010 Jan;37(1):13-25. doi: 10.1016/j.nbd.2009.07.030. Epub 2009 Aug 5.
PubMed 19664713
Wilcox JA, Jeng MY, Tischfield S, Sui JSY, Nemirovsky D, Heller G, Choudhury NJ, Ross JS, Rudin CM, Riely GJ, Kris MG, Donoghue M, Boire AA, Yu HA. Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases. Ann Oncol. 2025 Oct;36(10):1142-1153. doi: 10.1016/j.annonc.2025.06.001. Epub 2025 Jun 16.
PubMed 40532851
Jia C, Xu Q, Zhao L, Kong F, Jia Y. Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis. Transl Oncol. 2024 Jan;39:101832. doi: 10.1016/j.tranon.2023.101832. Epub 2023 Nov 25.
PubMed 38006761
Wang Y, Yang X, Li NJ, Xue JX. Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment. Lung Cancer. 2022 Dec;174:1-13. doi: 10.1016/j.lungcan.2022.09.013. Epub 2022 Oct 1.
PubMed 36206679

Study at a glance

From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Prospective Study of Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Therapy
ClinicalTrials.gov ID: NCT07551414
Acronym / sponsor ID: NCC6051
Conditions: NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation, Zorifertinib
Keywords: Leptomeningeal Metastasis, NSCLC, zorifertinib, EGFR-TKI Sensitizing Mutation
Phase: Phase 2
Study type: Interventional
Recruitment status: Not yet recruiting
Enrolment: 38 participants (estimated)
Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUniversity, hospital or other
Collaborators: Alpha Biopharma (Jiangsu) Co., Ltd.
Study start: 30 May 2026 (estimated)
Primary completion: 30 May 2027 (estimated)
Study completion: 30 May 2028 (estimated)
First posted: 24 Apr 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy

Detailed description

Study design

Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1
Model description: This study is a single-center, single-arm, open-label, prospective clinical study.

Arm	Type	Receives
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy	Experimental	Drug: Zorifertinib Plus Intra-Ommaya CSF ChemotherapyZorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Therapy

Who may qualify

Ages: 18 to 75 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (17 listed)

1. Have fully understood the study and voluntarily signed the Informed Consent Form (ICF).
2. Subjects must be 18-75 years old before signing the Informed Consent Form (ICF).
3. During the screening phase, subjects must be diagnosed with non-small cell lung cancer (NSCLC) and test positive for EGFR-sensitive mutations (L858R and/or Exon 19Del).
4. Subjects who developed leptomeningeal progression after treatment with third-generation EGFR-TKIs and have no extracranial progression. The original third-generation EGFR-TKIs may be continued at the original dose or reduced dose.
5. Subjects diagnosed with leptomeningeal metastasis must have positive cerebrospinal fluid (CSF) cytology results. Subjects with negative CSF cytology but clinically diagnosed leptomeningeal metastasis based on symptoms, brain or spinal MRI imaging are also eligible for enrollment.

Key exclusion criteria (21 listed)

1. Subjects with a history of cranial or spinal radiotherapy within 6 months prior to study drug administration are ineligible for enrollment. Radiotherapy for bone metastases within 3 months prior to study drug administration is also not permitted.
2. Subjects who have undergone major surgical procedures (e.g., intrathoracic, intra-abdominal, or pelvic surgery) within 4 weeks prior to the first dose of study treatment, or who have not yet recovered from side effects related to such surgeries, are ineligible for enrollment.
3. Subjects with any other currently active malignant tumor besides NSCLC are excluded.
4. Subjects with clinically significant, uncontrolled cardiac disease and/or cardiac events occurring within the past 6 months, such as:
6. Subjects unable to discontinue the following medications within 1 week prior to study drug administration and during the study period:

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Zorifertinib Plus Intra-Ommaya CSF ChemotherapyZorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Therapy	Drug	Zorifertinib Plus Intra-Ommaya CSF Chemotherapy

Primary outcome

Response Assessment in Neuro - Oncology Leptomeningeal Metastases (RANO - LM) criteria
Time frame: Until the end of the study (up to 3 years)
RANO-LM uses a categorical classification (no single numeric score range) to define disease status: Complete Response (CR): All LM-related lesions disappear, no increase in ventricular size. Partial Response (PR): All measurable LM nodules shrink by ≥50% (sum of perpendicular diameters), no increase in ventricular size. Stable Disease (SD): Neither PR nor Progressive Disease (PD) criteria are met. Progressive Disease (PD): Any of the following: 1. New measurable LM nodule(s); 2. ≥50% increase in the product of perpendicular diameters of any measurable nodule (≥25% if the largest diameter is <10mm); 3. ≥25% increase in Evan's index (marker of hydrocephalus progression); 4. New linear meningeal enhancement (excluding post-lumbar puncture changes).

1 secondary outcome

Overall Survival (OS)
Time frame: Until the end of the study (up to 3 years)

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
Background: PubMed 38377785Fan C, Jiang Z, Teng C, Song X, Li L, Shen W, Jiang Q, Huang D, Lv Y, Du L, Wang G, Hu Y, Man S, Zhang Z, Gao N, Wang F, Shi T, Xin T. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial. ESMO Open. 2024 Apr;9(4):102384. doi: 10.1016/j.esmoop.2024.102384. Epub 2024 Feb 19.
Background: PubMed 33989780Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Gao F, Song X, Jiang Q, Huang D, Jin Y, Lv Y, Wei L, Shi T, Zhao X, Gao N, Jiang Z, Xin T. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615). J Thorac Oncol. 2021 Aug;16(8):1359-1368. doi: 10.1016/j.jtho.2021.04.018. Epub 2021 May 11.
Background: PubMed 30524956Montes de Oca Delgado M, Cacho Diaz B, Santos Zambrano J, Guerrero Juarez V, Lopez Martinez MS, Castro Martinez E, Avendano Mendez-Padilla J, Mejia Perez S, Reyes Moreno I, Gutierrez Aceves A, Gonzalez Aguilar A. The Comparative Treatment of Intraventricular Chemotherapy by Ommaya Reservoir vs. Lumbar Puncture in Patients With Leptomeningeal Carcinomatosis. Front Oncol. 2018 Nov 20;8:509. doi: 10.3389/fonc.2018.00509. eCollection 2018.
Background: PubMed 16371949Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006 Jan;7(1):41-53. doi: 10.1038/nrn1824.
Background: PubMed 19664713Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010 Jan;37(1):13-25. doi: 10.1016/j.nbd.2009.07.030. Epub 2009 Aug 5.
Background: PubMed 40532851Wilcox JA, Jeng MY, Tischfield S, Sui JSY, Nemirovsky D, Heller G, Choudhury NJ, Ross JS, Rudin CM, Riely GJ, Kris MG, Donoghue M, Boire AA, Yu HA. Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases. Ann Oncol. 2025 Oct;36(10):1142-1153. doi: 10.1016/j.annonc.2025.06.001. Epub 2025 Jun 16.
Background: PubMed 38006761Jia C, Xu Q, Zhao L, Kong F, Jia Y. Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis. Transl Oncol. 2024 Jan;39:101832. doi: 10.1016/j.tranon.2023.101832. Epub 2023 Nov 25.
Background: PubMed 36206679Wang Y, Yang X, Li NJ, Xue JX. Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment. Lung Cancer. 2022 Dec;174:1-13. doi: 10.1016/j.lungcan.2022.09.013. Epub 2022 Oct 1.
Individual participant dataSharing planned: Yes. all IPD collected throughout the trial

Related trials for NSCLC (Non-small Cell Lung Carcinoma)

RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Wan Jinghai, Professor contact

8610-87788495

wanjinghai@sina.com

Wan Jinghai study chair

Chinese Academy of Medical Sciences

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Wan Jinghai, Professor (8610-87788495, wanjinghai@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Response Assessment in Neuro - Oncology Leptomeningeal Metastases (RANO - LM) criteria (time frame: Until the end of the study (up to 3 years)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07551414, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.